WO2014108808A3 - Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration - Google Patents

Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration Download PDF

Info

Publication number
WO2014108808A3
WO2014108808A3 PCT/IB2014/000606 IB2014000606W WO2014108808A3 WO 2014108808 A3 WO2014108808 A3 WO 2014108808A3 IB 2014000606 W IB2014000606 W IB 2014000606W WO 2014108808 A3 WO2014108808 A3 WO 2014108808A3
Authority
WO
WIPO (PCT)
Prior art keywords
trauma
formulations
neurodegeneration
cells
lithium
Prior art date
Application number
PCT/IB2014/000606
Other languages
French (fr)
Other versions
WO2014108808A2 (en
Inventor
James Lorne HENRY
Original Assignee
Henry James Lorne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry James Lorne filed Critical Henry James Lorne
Publication of WO2014108808A2 publication Critical patent/WO2014108808A2/en
Publication of WO2014108808A3 publication Critical patent/WO2014108808A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Novel multi-component formulations, procedures and methods for use in treating neuropathology and neurodegeneration incident to trauma are provided. Multi- component formulations of the invention comprise biologically active forms of any two, any three, or all four of at least one neurosteroid or neuroactive steroid, such as progesterone or synthetic progestin, at least one anti-epileptic or anticonvulsant, such as gabapentin, pregabalin or valproic acid, at least one NK-1 receptor antagonist, such as aprepitant, casopitant or vestipitant, at least one lithium-containing or lithium-related drug. The provided formulations are configured or adapted to prevent or reduce the incidence and severity of neurological damage caused by trauma, or the risk of such damage. Formulations, procedures and methods of the invention advantageously effect both neuroprotective actions to prevent or reduce secondary injuries, and neurotrophic actions to repair and restore cells and tissues affected by the trauma, and are especially useful in treating injury or trauma to nerve cells, to neural support cells and to neural support tissues.
PCT/IB2014/000606 2013-01-09 2014-01-07 Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration WO2014108808A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361750745P 2013-01-09 2013-01-09
US61/750,745 2013-01-09
US201461924212P 2014-01-06 2014-01-06
US61/924,212 2014-01-06

Publications (2)

Publication Number Publication Date
WO2014108808A2 WO2014108808A2 (en) 2014-07-17
WO2014108808A3 true WO2014108808A3 (en) 2014-10-30

Family

ID=51167471

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/000606 WO2014108808A2 (en) 2013-01-09 2014-01-07 Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration

Country Status (1)

Country Link
WO (1) WO2014108808A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
BR112014018110B1 (en) 2012-01-23 2022-06-07 Sage Therapeutics, Inc Aqueous pharmaceutical compositions formulated for parenteral administration and use of allopregnanolone and sulfbutylether-b-cyclodextrin
CA2892811A1 (en) 2012-11-30 2014-06-05 The Regents Of The University Of California Allopregnanolone and a sulfobutylether-b-cyclodextrin salt for the treatment of post-partum depression
US8992951B2 (en) 2013-01-09 2015-03-31 Sapna Life Sciences Corporation Formulations, procedures, methods and combinations thereof for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
SG10201802389SA (en) 2013-04-17 2018-04-27 Sage Therapeutics Inc 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof
LT2986624T (en) 2013-04-17 2020-07-10 Sage Therapeutics, Inc. 19-nor neuroactive steroids for methods of treatment
AU2014290400B2 (en) 2013-07-19 2019-12-05 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
PT3035940T (en) 2013-08-23 2019-01-28 Sage Therapeutics Inc Neuroactive steroids, compositions, and uses thereof
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CN105326784B (en) * 2014-08-08 2018-06-26 四川科瑞德制药股份有限公司 A kind of sodium vedproate parenteral solution
KR102612943B1 (en) 2014-10-16 2023-12-13 세이지 테라퓨틱스, 인크. Compositions and methods for treating cns disorders
EP3753927B1 (en) 2014-10-16 2023-07-19 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
PT3224269T (en) 2014-11-27 2020-06-01 Sage Therapeutics Inc Compositions and methods for treating cns disorders
SI3250210T1 (en) 2015-01-26 2021-07-30 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US10329320B2 (en) 2015-02-20 2019-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US20200306262A1 (en) * 2015-11-20 2020-10-01 Sage Therapeutics, Inc. Compounds and methods of their use
CN109414444A (en) 2016-03-08 2019-03-01 萨奇治疗股份有限公司 Neuroactive steroids, its composition and purposes
US20190233465A1 (en) 2016-07-11 2019-08-01 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
EP4302764A2 (en) 2016-07-11 2024-01-10 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
US20190175702A1 (en) * 2016-08-03 2019-06-13 Zhuhai Beihai Biotech Co., Ltd. Formulations of fosaprepitant and aprepitant
MX2021014515A (en) 2019-05-31 2022-03-22 Sage Therapeutics Inc Neuroactive steroids and compositions thereof.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009089024A1 (en) * 2008-01-08 2009-07-16 Duke University Neuroactive steroid compositions and methods of use therefor
WO2010077680A2 (en) * 2008-12-08 2010-07-08 Vm Discovery Inc. Compositions of protein receptor tyrosine kinase inhibitors
WO2010107815A1 (en) * 2009-03-16 2010-09-23 Duke University Neuroactive steroid compositions and methods of use therefor
US20110046090A1 (en) * 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
WO2012112340A2 (en) * 2011-02-18 2012-08-23 Nestec S.A. Methods and compositions for treating, reducing, or preventing damage to the nervous system of animals

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110046090A1 (en) * 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
US20110288059A1 (en) * 2007-01-08 2011-11-24 Marx Christine E Neuroactive steroid compositions and methods of use therefor
WO2009089024A1 (en) * 2008-01-08 2009-07-16 Duke University Neuroactive steroid compositions and methods of use therefor
WO2010077680A2 (en) * 2008-12-08 2010-07-08 Vm Discovery Inc. Compositions of protein receptor tyrosine kinase inhibitors
US20110301133A1 (en) * 2008-12-08 2011-12-08 Vm Pharma Llc Compositions of protein receptor tyrosine kinase inhibitors
WO2010107815A1 (en) * 2009-03-16 2010-09-23 Duke University Neuroactive steroid compositions and methods of use therefor
WO2012112340A2 (en) * 2011-02-18 2012-08-23 Nestec S.A. Methods and compositions for treating, reducing, or preventing damage to the nervous system of animals

Also Published As

Publication number Publication date
WO2014108808A2 (en) 2014-07-17

Similar Documents

Publication Publication Date Title
WO2014108808A3 (en) Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration
WO2014108809A3 (en) Multiple-component pharmaceutical formulations and methods for their use in treating neuropathology and neurodegeneration caused by traumatic injury
MX370543B (en) Vegf neutralizing prodrugs for the treatment of ocular conditions.
WO2017087608A8 (en) Modulators of ror-gamma
WO2012078593A3 (en) Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis
WO2017132432A8 (en) Benzimidazole derivatives as modulators of ror-gamma
WO2012037410A3 (en) Estrogen receptor modulators and uses thereof
WO2011156518A3 (en) Estrogen receptor modulators and uses thereof
WO2012009171A3 (en) Compositions and methods of treatment of corneal endothelium disorders
WO2011159769A3 (en) Indane estrogen receptor modulators and uses thereof
WO2011007230A3 (en) Lupeol-type triterpene derivatives as antivirals
WO2017070647A8 (en) Nicotinamide for use in the treatment and prevention of ocular neurodegenerative disorder (e.g. glaucoma)
WO2015138628A8 (en) Use of aav-expressed m013 protein as an anti-inflammatory therapeutic
SG10201907588XA (en) Androgen Receptor Modulators And Uses Thereof
WO2013170012A3 (en) Proliposomal testosterone formulations
EP4218823A3 (en) Novel polymeric hgh prodrugs
MX2014010537A (en) Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions.
MX2019006877A (en) 4 - pregenen- 11ss - 17 - 21 -triol-3, 20 -dione derivatives for the treatment of ocular conditions.
EP3345929A4 (en) Fusion polypeptide in which anti-inflammatory polypeptide and ferritin monomer fragment are bound and pharmaceutical composition for preventing and treating inflammatory diseases, containing same as active ingredient
EA036036B1 (en) Compositions comprising cyclosporin
WO2015048188A3 (en) Modified fibroblast growth factors for the treatment of ocular disorders
CA2894715C (en) Diazole amides
PH12014501573A1 (en) Topical pharmaceutical compositions comprising bexarotene and a corticosteroids
WO2017056109A3 (en) Novel forms of lumacaftor and processes for the preparation thereof
WO2013051816A3 (en) Cell treatment application system for dealing with skin defects, and cell harvesting unit, pulverizing unit, and atomizing unit for same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14737869

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14737869

Country of ref document: EP

Kind code of ref document: A2